ABT-869 is a dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.003, 0.004, 0.004, 0.19, 0.066, 0.003, and 0.014 µM for VEGFR1, VEGFR2, FLT3, VEGFR3, PDGFRbeta, CSF-1R, and KIT, respectively). It is selective for these kinases over other tyrosine kinases, including RET, FGFR, Src, EGFR, and c-Met (IC50s = 1.9,...

Soluble in DMSO or ethanol. Linifanib (A 741439, A-741439, A741439, ABT-869, ABT869, RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors...